ReviewPharmaceuticals (Basel, Switzerland)2010
Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action.
Review in Pharmaceuticals (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- Blood retinol and retinol-binding protein concentrations are associated with diabetes: a systematic review and meta-analysis of observational studies.European journal of nutrition · 2022Pooled it
- Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review.Frontiers in public health · 2021Pooled it
- Dose and time-response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients combined or not with hypoglycemic medicine: A randomized, crossover, double-blind, sham-controlled trial.Journal of biophotonics · 2023Trial
- Exploring the Effects of Short-Term Daily Intake ofNutrients · 2023Trial
- Efficacy of a language-concordant health coaching intervention for latinx with diabetes.Patient education and counseling · 2022Trial
- Trial
- Randomized double-blinded pilot clinical study of the antidiabetic activity of Balanites aegyptiaca and UPLC-ESI-MS/MS identification of its metabolites.Pharmaceutical biology · 2017Trial
- In Vivo Therapeutic Potential of Biologically Synthesized Nanoparticles From Pine Needle Leaf Extract in Streptozotocin-Induced Diabetic Rats.BioMed research international · 2026Article
- From guidelines to practice: an Egyptian expert opinion on type 2 diabetes mellitus management in primary care settings.BMC primary care · 2025Article
- Antidiabetic Activity of Silver Nanoparticles Biosynthesized withPharmaceuticals (Basel, Switzerland) · 2025Article
- Antimicrobial, antidiabetic, antiviral, and antioxidant activities of fucoidan extracted from the brown seaweed Padina pavonica.BMC biotechnology · 2025Article
- Formulation and evaluation of PVA-sucrose dissolving microneedles loaded with glimepiride nanocrystals as a potential transdermal delivery system.RSC advances · 2025Article
- Mechanism of trypsin-mediated differentiation of pancreatic progenitor cells into functional islet-like clusters.World journal of diabetes · 2025Article
- Use of Antihyperglycemic Medications Among US People with Limited English Proficiency.Journal of general internal medicine · 2025Article
- Therapeutic potential ofFrontiers in nutrition · 2025Review
- Heat-moisture-treated rice improves oral glucose tolerance by modulating serum and fecal metabolites in mice.Frontiers in nutrition · 2025Article
- Hypoglycaemic Principles ofBiochemistry research international · 2025Article
- Advance Glycation End Products Inhibition byFood science & nutrition · 2024Article
- Review
- A Dual Therapeutic Approach to Diabetes Mellitus via Bioactive Phytochemicals Found in a Poly Herbal Extract by Restoration of Favorable Gut Flora and Related Short-Chain Fatty Acids.Applied biochemistry and biotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) include diet and exercise as first-line therapy plus hypoglycemic drugs. Actually there are seven distinct classes of anti-hyperglicemic agents, each of them displaying unique pharmacologic properties. The aim of this review is to describe the pathophysiological basis of their mechanism of action, a necessary step to individualize treatment of diabetic people, taking into proper consideration potential benefits and secondary effects of drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.